Brief: Clovis Oncology Submits Investigational New Drug Applications For Novel Peptide-Targeted Radionuclide Fap-2286 For Therapeutic And Imaging Clinical Trial
29/12/2020 13:01
Dec 29 (Reuters) - Clovis Oncology Inc CLVS.O :
* CLOVIS ONCOLOGY SUBMITS INVESTIGATIONAL NEW DRUG
APPLICATIONS
FOR NOVEL PEPTIDE-TARGETED RADIONUCLIDE FAP-2286 FOR THERAPEUTIC
AND IMAGING CLINICAL TRIAL
* CLOVIS ONCOLOGY - INITIATION OF PHASE 1/2 CLINICAL STUDY
OF
NOVEL PEPTIDE-TARGETED RADIONUCLIDE THERAPY & IMAGING AGENT
TARGETING FAP EXPECTED 1H 2021
Source text for Eikon: ID:nBw3hkyjwa
Further company coverage: CLVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clovis Oncology
See all newsBrief: Clovis Oncology Inc - On April 5, 2023, Entered Into Asset Purchase Agreement With Pharma& To Sell Product Business For Upfront Payment Of $70 Million
Brief: Clovis Oncology Enters Into Financing Agreement
Brief: Clovis Oncology Inc Received Written Notice From Nasdaq That Company's Common Stock Will Be Delisted From Nasdaq
U.S. STOCKS ON THE MOVE-Nike, Faraday Future, PBF Energy
U.S. STOCKS ON THE MOVE-Natural gas, Box Inc, Weber